Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study DOI Creative Commons
Gi‐Ae Kim, Seogsong Jeong, Heejoon Jang

et al.

Liver Cancer, Journal Year: 2023, Volume and Issue: 13(4), P. 426 - 437

Published: Dec. 22, 2023

<b><i>Introduction:</i></b> This study aimed to investigate the liver-related outcomes of newly suggested metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD), as well alcohol-associated (ALD). <b><i>Methods:</i></b> From a National Health Insurance Service Screening Cohort, we included 369,094 participants who underwent health checkups between 2009 2010 in South Korea. Steatotic (SLD) was defined fatty index ≥60. The risk primary cancer (PLCa), hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), incident cirrhosis, decompensated cirrhosis compared no SLD. subdistribution hazard ratio (SHR) calculated using Fine-Gray model regarding competing risks. <b><i>Results:</i></b> A total 3,232 (0.9%) developed PLCa during median follow-up 3,227,176 person-years: 0.5% SLD, 1.1% MASLD, 1.3% MetALD, 1.9% ALD. Competing analysis revealed that (SHR: 1.65; 95% CI: 1.44−1.88), MetALD 1.87; 1.52−2.29), ALD 1.86; 1.39−2.49) were associated an PLCa. 1.96; 1.67−2.31), 2.23; 1.75−2.84), 2.34; 1.67−3.29) higher HCC. No significant difference observed iCCA. order <b><i>Conclusion:</i></b> have PLCa, HCC, but not These findings may serve robust ground for prognostic value MetALD.

Language: Английский

MAFLD: How is it different from NAFLD? DOI Creative Commons
Cameron Gofton,

Yadhavan Upendran,

Ming‐Hua Zheng

et al.

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(Suppl), P. S17 - S31

Published: Nov. 29, 2022

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer related systemic metabolic dysregulation. The name change from nonalcoholic (NAFLD) MAFLD comes with a simple set of criteria enable easy diagnosis at bedside for general medical community, including primary care physicians. Since introduction term, there have been key areas which superiority over traditional NAFLD terminology has demonstrated, risk and extrahepatic mortality, associations, identifying high-risk individuals. Additionally, adopted by number leading pan-national national societies due its concise diagnostic criterion, removal requirement exclude concomitant diseases, reduction stigma associated this condition. current article explores differences between diagnosis, benefit, some potential limitations, how opened up new fields research.

Language: Английский

Citations

245
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease DOI
Hyeok‐Hee Lee, Han Ah Lee,

Eun-Jin Kim

et al.

Gut, Journal Year: 2023, Volume and Issue: unknown, P. gutjnl - 331003

Published: Oct. 31, 2023

Objective We explored clinical implications of the new definition metabolic dysfunction-associated steatotic liver disease (MASLD) by assessing its prevalence and associated cardiovascular (CVD) risk. Design From nationwide health screening data, we identified 9 775 066 adults aged 20–79 who underwent examination in 2009. Participants were categorised into four mutually exclusive groups: (1) MASLD; (2) MASLD with increased alcohol intake (MetALD); (3) other combined aetiology (the three collectively referred to as MASLD/related (SLD)); (4) no SLD. SLD was determined fatty index ≥30. The primary outcome CVD event, defined a composite myocardial infarction, ischaemic stroke, heart failure or death. Results MASLD, MetALD 27.5%, 4.4% 1.5%, respectively. A total 8 808 494 participants without prior followed up for median 12.3 years, during which 272 863 events occurred. cumulative incidence multivariable-adjusted risk higher than those (HR 1.38 (95% CI 1.37 1.39)). Multivariable-adjusted HR CI) 1.39 (1.38 1.40) 1.28 (1.26 1.30) 1.30 1.34) compared absence any these conditions. also non-alcoholic respective condition. Conclusion Over one-third Korean have bear high

Language: Английский

Citations

85
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives DOI Creative Commons
Shang‐Chin Huang, Chun‐Jen Liu

Clinical and Molecular Hepatology, Journal Year: 2023, Volume and Issue: 29(2), P. 320 - 331

Published: Feb. 2, 2023

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although is a well-known risk factor for adverse outcomes like cirrhosis hepatocellular carcinoma, its interactions with virus (HBV) clinical impacts seem complex. presence hepatic steatosis may suppress HBV viral activity, potentially leading to attenuated injury. In contrast, associated co-morbidities diabetes mellitus or obesity increase developing outcomes. These findings implicate that components MAFLD have diverse effects on manifestations CHB. To this end, strategy proposed managing concurrent CHB MAFLD. This review article discusses updated evidence regarding prevalence, between HBV, impacts, management strategies, aiming at optimizing holistic health care in population.

Language: Английский

Citations

45
Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation DOI Creative Commons

Byeong Hyun Min,

Shivani Devi,

Goo Hyun Kwon

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: Feb. 1, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic disease, and its prevalence has increased worldwide in recent years. Additionally, there a close relationship between MASLD gut microbiota-derived metabolites. However, mechanisms of metabolites are still unclear. We demonstrated decreased indole-3-propionic acid (IPA) indole-3-acetic (IAA) feces patients with hepatic steatosis compared to healthy controls. Here, IPA IAA administration ameliorated inflammation an animal model WD-induced by suppressing NF-κB signaling pathway through reduction endotoxin levels inactivation macrophages. Bifidobacterium bifidum metabolizes tryptophan produce IAA, B. effectively prevents production IAA. Our study demonstrates that derived from microbiota have novel preventive or therapeutic potential for treatment.

Language: Английский

Citations

31
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease DOI Creative Commons
Ziyan Pan, Moutaz Derbala, Khalid Al‐Naamani

et al.

Annals of Hepatology, Journal Year: 2024, Volume and Issue: 29(5), P. 101512 - 101512

Published: May 6, 2024

Fatty liver disease is a multisystem disease. Metabolic dysfunction-associated fatty (MAFLD) more accurate indicator of chronic kidney (CKD) than nonalcoholic (NAFLD). However, the relationship between recently defined metabolic steatotic (MASLD) and CKD currently unclear. The objective this cross-sectional study was to investigate prevalence albuminuria among individuals diagnosed with either MAFLD or MASLD.

Language: Английский

Citations

20
MAFLD identifies patients with significant hepatic fibrosis better than MASLD DOI
Ziyan Pan, Said A. Al‐Busafi, Maheeba Abdulla

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(3), P. 964 - 972

Published: May 8, 2024

Language: Английский

Citations

19
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study DOI
Eugene Han, Byung‐Wan Lee, Eun Seok Kang

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 152, P. 155789 - 155789

Published: Jan. 13, 2024

Language: Английский

Citations

18
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease DOI Creative Commons
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu

et al.

Hepatology International, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Language: Английский

Citations

5
MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups DOI
Hyoeun Kim, Chan Joo Lee, Sang Hoon Ahn

et al.

Digestive Diseases and Sciences, Journal Year: 2022, Volume and Issue: 67(10), P. 4919 - 4928

Published: May 17, 2022

Language: Английский

Citations

47
MAFLD: an optimal framework for understanding liver cancer phenotypes DOI Creative Commons
Harry Crane, Cameron Gofton, Ankur Sharma

et al.

Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 58(10), P. 947 - 964

Published: July 20, 2023

Hepatocellular carcinoma has a substantial global mortality burden which is rising despite advancements in tackling the traditional viral risk factors. Metabolic (dysfunction) associated fatty liver disease (MAFLD) most prevalent disease, increasing parallel with epidemics of obesity, diabetes and systemic metabolic dysregulation. MAFLD major factor behind this sustained rise HCC incidence, both as single entity often via synergistic interactions other diseases. Mechanisms MAFLD-related are complex but crucially underpinned by dysregulation variable contributions from interacting modifiers related to environment, genetics, dysbiosis immune distinct clinical presentation, notably its common occurrence non-cirrhotic disease. This just one several challenges effective surveillance programmes. The response immune-checkpoint therapy currently controversial, further complicated high prevalence individuals aetiologies. In review, we highlight current data on epidemiology, characteristics, outcomes screening controversies. addition, concepts that have arisen because paradigm such MAFLD/NAFLD non-overlapping groups, dual aetiology tumours sub-phenotypes reviewed.

Language: Английский

Citations

27